Decheng Capital LLC
CIK 0002010850 · MENLO PARK, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$731.7M
2026 Q2
Positions
14
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
98.1%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
CGON
CG ONCOLOGY INC
61.9%
NUVB
Nuvation Bio Inc.
20.1%
AARD
AARDVARK THERAPEUTICS INC
3.1%
ACRS
Aclaris Therapeutics, Inc.
2.9%
UPB
Upstream Bio Inc.
2.6%
RCUS
Arcus Biosciences, Inc
2.0%
EQ
Equillium Inc.
1.9%
RVMD
REVOLUTION MEDICINES INC(NSM)
1.3%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.